Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > New COC Nutrition class added
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(41)
•••
Post by LithLoveron Oct 08, 2024 6:14pm
98 Views
Post# 36258551

New COC Nutrition class added

New COC Nutrition class added

Fall Nutrition Workshops with the Source

We are continuing with our Nutrition Classes. The next session is October 24, 2024 and will be focused on nutrition for Breast Cancer. Sign up below for the class.

Additional classes focusing on Gut Health & the Microbiome and Prostate cancer will follow next month.

The solution is to screen for and detect cancer early.  Aristotle® is a multi-cancer test panel that uses mRNA technology to simultaneously detect multiple cancer signatures from a single sample of blood. In addition, to prostate cancer 

Aristotle® screens for eight additional cancers including bladder and colorectal.

Finding cancer early can dramatically affect the outcome.  Care Oncology is committed to working with its patients to improve overall outcomes.

-------------------------------------

This is all well and good but we need those Aristotle tests. 

Where are the partnership announcements?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities